APLS
Apellis Pharmaceuticals Inc
NASDAQ · Biotechnology
$23.49
+0.93 (+4.12%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 797.89M | 3.03B | 2.81B | 3.40B |
| Net Income | -202,060,754 | 93.04M | 81.85M | 92.75M |
| EPS | — | — | — | — |
| Profit Margin | -25.3% | 3.1% | 2.9% | 2.7% |
| Rev Growth | +127.2% | +21.3% | +20.6% | +22.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 987.60M | 1.16B | 884.37M | 986.26M |
| Total Equity | 498.44M | 2.04B | 1.97B | 2.09B |
| D/E Ratio | 1.98 | 0.57 | 0.45 | 0.47 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -170,834,333 | 115.17M | 115.66M | 126.47M |
| Free Cash Flow | — | 42.87M | 48.47M | 53.10M |